PureTech announces receipt of FDA Fast Track Designation for LYT-200 in AML
PureTech Health (PRTC) announced that the U.S. Food and Drug Administration has granted Fast Track designation to LYT-200, a ...
PureTech Says FDA Grants Fast Track Designation For LYT-200 In Acute Myeloid Leukemia
Biotherapeutics company PureTech Health plc (PRTC) announced Thursday that the U.S. Food and Drug Administration (FDA) has granted ...
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
LYT-200 exerts its therapeutic effects in AML by killing cancer cells directly via apoptosis and DNA damage as well as reactivating central anti-cancer effectors of the immune system. LYT-200 is the ...
PureTech Drug Gets FDA Fast-Track Designation for Leukemia
The biotherapeutics company said the treatment, LYT-200, is being evaluated in two ongoing clinical trials. It was previously granted orphan drug designation for the treatment of acute myeloid ...
PureTech to Present at 43rd Annual J.P. Morgan Healthcare Conference
About PureTech Health PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company ...
PureTech receives FDA fast track designation for leukemia treatment
(Alliance News) - PureTech Health PLC on Thursday said that the US Food & Drug Administration has granted fast track designation to its antibody LYT-200 for the treatment of acute myeloid leukemia.
PureTech Health (NASDAQ:PRTC) Trading Down 6.3% – Should You Sell?
Shares of PureTech Health plc (NASDAQ:PRTC – Get Free Report) were down 6.3% on Thursday . The stock traded as low as $17.04 and last traded at $17.55. Approximately 6,778 shares traded hands during ...
news.stocktradersdaily19h
Trading (PRTC) With Integrated Risk Controls
GET MORE AI-GENERATED SIGNALS: January 10, 2025, 20:42 pm ET, BY Rick W.- Contributor| Editor: Thomas H. Kee Jr. ( Follow on LinkedIn) Short PRTC slightly under 20.06, target 16.8, stop loss @ 20.12 ...
Business Wire5d
PureTech Appoints UBS as UK Corporate Broker
BOSTON--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed UBS as its UK Corporate Broker.
PharmiWeb5d
PureTech Appoints UBS as UK Corporate Broker
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), is pleased to announce that it has appointed UBS as its UK Corporate Broker. About PureTech Health PureTech is a ...
Yahoo Finance5d
PureTech Appoints UBS as UK Corporate Broker
PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and ...
Nasdaq5d
PureTech Health Appoints UBS as UK Corporate Broker
PureTech Health has appointed UBS as its UK Corporate Broker, a strategic move likely to enhance its financial operations and market positioning in the UK. This partnership could potentially ...